Lakefront Biotherapeutics (LKFT) news
Recent news
Lakefront Biopharma NV - Gamgertamig in Phase 2 studies; registration studies expected in 2027
Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) has announced that gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, is currently in Phase 2 studies and enter registrational studies as early as 2027. The drug candidate, which has been granted both Fast Track and Orphan Drug…
AInvest Wire · 6d agoLakefront Biopharma reports half-year 2026 financial results and provides business update
AInvest Wire · Aug 10, 2026Lakeland Industries: expect revenue growth, margin improvement, & EBITDA expansion to become more visible in back half of FY27
Lakeland Industries, Inc. (NASDAQ: LAKE) has outlined a strategic path toward revenue growth, margin improvement, and EBITDA expansion, with expectations that these trends will become more pronounced in the back half of fiscal year 2027 (FY27). The company’s recent financial performance and…
AInvest Wire · Jun 9, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.